ACTU
ACTU clinical trials: ACTUATE THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where ACTUATE THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 5
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ACTU on the catalyst calendar · ACTU registry changes
- Primary completion Jul 2029Sponsor estimatePhase 1/Phase 2NCT07714395Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid TumorsActuate Therapeutics Inc. · Advanced Malignant Solid TumorNot yet recruitingACTULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 2NCT036788839-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc. · CancerActive, not recruitingACTULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2025ActualPhase 1NCT042390929-ING-41 in Pediatric Patients With Refractory Malignancies.Actuate Therapeutics Inc. · Refractory CancerTerminatedACTULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2022ActualPhase 2NCT04218071Actuate 1901: 9-ING-41 in MyelofibrosisActuate Therapeutics Inc. · MyelofibrosisCompletedACTULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2033Sponsor estimatePhase 2NCT048324389-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaActuate Therapeutics Inc. · Salivary Gland CarcinomaWithdrawnACTULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 14, 2025ActualPhase 2NCT050106299-ING-41 Plus Carboplatin in Salivary Gland CarcinomaRobert Haddad, MD · Salivary Gland CancerActive, not recruitingACTUCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2028Sponsor estimatePhase 1NCT068961889-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)Anwaar Saeed · Pancreatic AdenocarcinomaRecruitingACTUCollaboratorINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05077800FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerColin D. Weekes, M.D., PhD · Pancreatic AdenocarcinomaActive, not recruitingACTUCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2022ActualPhase 2NCT052391829-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic AdenocarcinomaAnwaar Saeed · Pancreatic AdenocarcinomaTerminatedACTUCollaboratorINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2025Sponsor estimatePhase 2NCT05116800Phase 2 Study of 9-ING-41 With Chemotherapy in SarcomaBrown University · Soft Tissue SarcomaWithdrawnACTUCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2022Sponsor estimatePhase 2NCT04906876A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced SarcomasBrown University · SarcomaWithdrawnACTUCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner